Omeros' OMS721 shows positive effect in mid-stage IgA nephropathy study in steroid -free patients

|About: Omeros Corporation (OMER)|By:, SA News Editor

Omeros (OMER -5.3%) announces positive results from a Phase 2 clinical trial evaluating OMS721 in corticosteroid therapy-naive patients with immunoglobulin A (IgA) nephropathy.

The treatment effect, reductions in urine protein levels, was on par with that observed in IgA nephropathy patients on steroid therapy.

Additional data will be submitted for presentation at a future medical conference.

A Phase 3 study, ARTEMIS-IGAN, is ongoing with an estimated primary completion date of May 2020.

Shares will resume trading at 2:45 pm ET.

Subscribe for full text news in your inbox